Table 5 Upgrade to invasive cancer among patients with ductal carcinoma in situ on core needle biopsy who underwent surgical excision but who would have been eligible for active surveillance trials.

From: Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy

Study

Trial criteria

#

Upgrade to invasive cancer at surgical excision

Pilewskie et al. [38]

LORIS

296

58 (20%)

Grimm et al. [39]

COMET

81

5 (6%)

 

LORIS

74

5 (7%)

 

LORD

10

1 (10%)

Jakub et al. [40]

LORIS

241

16 (7%)

Patel et al. [41]

COMET

23

5 (22%)

 

LORIS

25

6 (24%)

Back to article page